PJRC(SH:600395)2020-10-30 16:00Financial Performance - Net profit attributable to shareholders was CNY 599,513,907.53, a decrease of 39.77% year-on-year[12]. - Operating income for the first nine months was CNY 4,822,390,434.71, down 15.43% from the same period last year[12]. - The company reported a loss of CNY 728,933.06 from the disposal of non-current assets during the third quarter[14]. - The company’s basic earnings per share decreased to CNY 0.362, down 39.77% from the previous year[12]. - Net profit decreased by 41.33% year-on-year, with self-produced premium coal sales volume down by 98,100 tons, leading to a revenue drop of ¥121,936,500[22]. - The company reported a net profit of ¥1,918,448,432.39, down from ¥1,980,955,269.26, a decrease of approximately 3.1%[32]. - The total profit for Q3 2020 was CNY 286,092,717.77, down from CNY 370,645,235.66 in Q3 2019, highlighting a decline in profitability[41]. - The company reported a net profit from the merged entity prior to consolidation of CNY 67,840,092.96, compared to CNY 175,707,885.66 from the previous period[45]. Revenue and Costs - Total operating revenue declined by 15.43% to ¥4,822,390,434.71 from ¥5,702,297,577.79, mainly impacted by falling coal prices[19]. - Total operating revenue for Q3 2020 was CNY 1,703,409,626.89, a decrease of 8.83% compared to CNY 1,868,955,435.21 in Q3 2019[39]. - Total operating costs for Q3 2020 were CNY 1,440,184,842.49, down from CNY 1,502,936,335.97 in Q3 2019, reflecting a cost reduction strategy[39]. - The average selling price of commodity coal decreased by ¥110.47 per ton, resulting in a revenue loss of ¥64,359,710[22]. - The total operating revenue for Q3 2020 was CNY 1,463,123,781.97, a decrease of 9.36% compared to CNY 1,614,981,830.39 in Q3 2019[45]. Cash Flow - Net cash flow from operating activities was CNY 551,477,386.49, a decline of 59.73% compared to the previous year[12]. - The net cash flow from operating activities for the first three quarters of 2020 was CNY 551,477,386.49, down 59.8% from CNY 1,369,534,899.55 in the previous year[50]. - The total cash outflow from operating activities was CNY 3,854,115,181.55, a decrease of 5.7% compared to CNY 4,087,209,568.13 in 2019[50]. - The cash inflow from investment activities was CNY 34,123,157.46, significantly lower than CNY 89,853,813.71 in the same period last year[52]. - The net cash flow from investment activities was -CNY 1,075,554,864.37, compared to -CNY 502,832,181.21 in 2019, indicating a worsening investment position[52]. - Cash inflow from financing activities increased to CNY 2,079,118,393.50 in 2020, up from CNY 1,465,400,000.00 in the previous year[52]. - The net cash flow from financing activities was CNY 94,132,546.99, a recovery from -CNY 358,343,547.43 in 2019[52]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 16,643,393,471.96, an increase of 0.42% compared to the end of the previous year[12]. - Total liabilities rose to ¥9,035,740,902.39 from ¥8,247,791,688.21, indicating an increase of approximately 9.6%[30]. - Current liabilities increased to ¥5,559,969,247.64 from ¥4,556,813,249.27, a rise of about 22%[30]. - The total assets reported were CNY 12,604,761,370.13, slightly up from CNY 12,524,905,895.26, indicating stable asset management[38]. - The total liabilities were reported at 8,247,791,688.21 CNY, with current liabilities at 4,556,813,249.27 CNY and non-current liabilities at 3,690,978,438.94 CNY[62]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,792, with the largest shareholder holding 58.07% of the shares[16]. - Total equity attributable to shareholders decreased to ¥6,963,243,658.60 from ¥7,702,986,627.33, a decrease of about 9.6%[32]. - Shareholders' equity decreased to CNY 6,838,931,567.71 from CNY 7,264,716,447.96, reflecting a reduction in retained earnings[38]. Research and Development - Research and development expenses increased by 17.54% to ¥112,315,022.64 from ¥95,557,830.15, reflecting the company's commitment to enhancing technological development[19]. - Research and development expenses for Q3 2020 amounted to CNY 56,853,460.76, a decrease from CNY 71,069,217.33 in Q3 2019, showing a focus on cost management[39]. - Research and development expenses for Q3 2020 were CNY 42,725,709.41, a decrease of 32.67% from CNY 63,391,099.74 in Q3 2019[45].